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Potential HIV dual inhibitors 
——— 
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The HIV-1 integrase (IN) is a well-established target in 
the long-lasting fight against AIDS. Many integrase 
inhibitors (INIs) have been developed since Shionogi and 
Merck scientists disclosed years ago that derivatives of 
2,4-dioxobutanoic acids (so-called diketo acids) blocked 
the strand transfer capability of the viral integrase.1 Other 
small molecules sharing the same pharmacophoric 
elements, such as bioisosteric 5-(1,3-dioxopropyl)-
tetrazoles or heteroaromatic substrates were soon 
designed and synthesised. Famous INIs are depicted in 
Figure 1 in their Mg2+-complexing anionic forms;2 the 
outstanding one is yet raltegravir (Isentress, approved by 
FDA in 2007).3 Nevertheless, as expected owing to the fast 
HIV-1 mutations, resistance against raltegravir has 
appeared as well.4 Alternative INIs with independent 
resistance profiles and drug candidates tackling other steps 
of the HIV life cycle are always a must. 
Conjugation of the pharmacophore—a Mg2+-chelating 
moiety with a hydrophobic 4-fluorobenzyl group—with 
nucleosides could favour the trans-membrane transport of 
the new chemical entities and might “simplify” their cata-
bolism affording less toxic metabolites. We also believed that 
conjugation of the pharmacophore with a nucleoside reverse 
transcriptase inhibitor (NRTI) could give rise to molecules of 
potentially synergic, dual effect (both NRTI and INI).5 
 
Figure 1. Common pharmacophoric elements of representative INIs. 
We planned to link tetrazole or 1,2,3-triazole rings, via the 
formation of a 1,3-dioxo moiety, to nucleosides, without 
disturbing the key features of the latter. We chose thymidine 
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and 3’-azido-3’-deoxythymidine (AZT, zidovudine) as 
working models (Figure 2). If we were able to generate such 
conjugates, we could apply the concept to a number of cases 
by linking other nucleosides and NRTIs to related INI 
moieties (e.g., to the 5-hydroxypyrimidinone substructure of 
raltegravir and its congeners). We report here our first 
approach: the synthesis of molecules such as those at the left 
side of Figure 2, with the nucleoside and the hydrophobic 
group at opposite sites of the chelating group. 
 
Figure 2. Examples of possible thymidine derivatives linked to Mg2+-
chelating moieties and to hydrophobic groups. 
In this context, we evaluated first the effect of the 
attachment of simple (but relatively polar) substituents to 
appropriate positions of AZT. The activity against wild-
type HIV-1 (NL4-3)6 of the samples shown in Figure 3 
(1a–f), prepared in our lab,7 clearly indicated that polar 
organic groups attached to position 3 (N3) of the thymine 
ring of AZT reduced slightly or only moderately its 
activity (but not by a factor of let’s say 103, which would 
have made our objective nonsense). 
 
Figure 3. Anti-HIV-1 (effective concentration, EC50) activities and 
cytotoxicities (CC50) of N3-substituted AZTs. EC50 values for AZT are 
in the 2–7 nM range (mean value, 3 nm), under the conditions of Ref. 6, 
for different bioassays performed during three years. 
Thus, the thymidine kinase seems capable of converting 
these N3-substituted AZTs8 into their phosphate esters 
(subsequently phosphorylated up to the triphosphate esters) 
and incorporate them into the nascent viral DNA, as any 
other chain-terminating NRTI. 
The technical problem of the preparation of tetrazoles 
C5-substituted with COCH3 or related electron-with-
drawing groups (EWGs), under very mild conditions, was 
solved by us time ago by means of a Cu2(OTf)2-catalysed 
cycloaddition.9 Moreover, the preparation of 1,2,3-triazole 
derivatives by Cu(I)-catalyzed alkyne–azide cycloaddition 
(CuAAC, Sharpless’ “click chemistry”) is currently a 
subject of great scope.10 We applied these two “click” 
reactions to 4-fluorobenzyl azide (Scheme 1), to prepare 2 
and 3. Following own protocols,7 we prepared nucleoside 
substrates represented by structure 4. Among various 
attempted condensation reactions,11 only the coupling of 
an excess of lithium enolates of 2 and 3, at low 
temperature, with appropriate nucleoside derivatives 4 
and 5 (with Z = CN) afforded satisfactory results.12 
 
Scheme 1. Preparation of starting materials. 
With all this information in hand, we performed the 
syntheses summarised in Scheme 2. We obtained 
aldehydes 4 (Z = H) and 5 (Z = H), for the first time, from 
the corresponding nucleosides (TBS-diprotected thymidine, 
as a model for checking the reactions, and TBS-protected 
AZT) and freshly prepared propynal in the presence of 
DMAP, in CH2Cl2–CH3CN at rt. We treated them with 
trimethylsilyl cyanide; the silylated cyanohydrins were 
oxidised in situ with 2,3-dichloro-5,6-dicyano-p-benzo-
quinone (DDQ) in moist 1,4-dioxane,13 to give 4 (Z = CN) 
and 5 (Z = CN) in 75–85% overall yields. In the most 
delicate step (the most prone to give rise to decomposition 
of the nucleoside substrates), these 2-oxonitrils were 
added drop-wise at –78ºC to 2 and 3 (220 mol%), to 
afford 6–9 in 44–70% yields.14 
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Scheme 2. Synthesis of the AZT derivatives 10 and 11. 
Finally, the TBS protecting groups of AZT derivatives 
8 and 9 were removed with Bu4N
+F–·3H2O (TBAF), to 
give the desired AZT derivatives, 10 and 11,15 in 74% and 
90% yields, respectively. 
The integrase strand-transfer inhibitory activities of 10 
and 11 (enzyme inhibitory concentrations, IC50)
16 are 
collected in Table 1, together with their effective 
concentrations (EC50) and cytotoxic concentrations (CC50) 
under the conditions indicated16 (which differ from those of 
Ref. 6 but are useful for comparison). Compound 10 
showed a low INI activity (see Table 1, entry 2, IC50 = 350 
µM) while that of 11 (entry 3) was undetectable; an 
additional chelating group or atom (COO–, OH, CONH or 
heterocyclic N) closer to the enol-enone moiety is probably 
required. On the other hand, 10 and 11 were almost as 
active as AZT as far as EC50 values
16 are concerned 
(compare entries 2 and 3 to entry 4), a fact that we expected 
(see the preceding page) but it had to be demonstrated. In 
this context, we should stress that 11 was more cytotoxic 
than AZT, so that we will discontinue the optimisation of 
this triazole derivative (of triazole derivatives in general); 
since thymidine derivatives also appeared to be cytotoxic 
(e.g., TBS-deprotected 7, CC50 = 6 µM), we ruled out them 
for future improvements as well. Only tetrazole derivative 
10, among 6–11, might become a lead. 
Table 1.  HIV-1 integrase inhibitory concentration (IC50), antiviral 
activity (EC50) and cytotoxicities (CC50) of 10 and 11 as compared to 
raltegravir and AZT.a 
entry compound IC50 (µM) EC50 (µM) CC50 (µM) 
1 raltegravir  0.004 0.005 1000 
2 10 350 0.240   130 
3 11  n.a. 0.160       8 
4 AZT — 0.150   200 
a Under the conditions of Ref. 16; n.a. = not active (> 800 µM). 
In summary, we have been fortunate to obtain for the 
first time representative conjugates of nucleosides and 1,3-
dioxopent-4-enyl derivatives of tetrazole and 1,2,3-triazole. 
Condensation of 5-acetyl-1-(4-fluorobenzyl)tetrazole and 
4-acetyl-1-(4-fluorobenzyl)-1,2,3-triazole with nucleoside-
derived 2-oxonitriles (never reported so far in the nucleoside 
field, a reaction only successful with aromatic substrates) 
was the method of choice. The key synthetic challenges have 
been solved. The integrase inhibition activity of the most 
promising “minimalistic” candidate (10) is still insufficient, 
but we have demonstrated that it keeps the features of AZT 
derivatives. Syntheses of other conjugates, more advanced 
prototypes with one further Mg2+-chelating group on 10, are 
under way. 
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99.0 (CH), 109.7 (C), 116.3 (d, J = 22.0, CH), 117.9 (CH), 125.1 
(CH), 129.7 (d, J = 3.0, C), 130.2 (d, J = 8.5, CH), 130.9 (CH), 
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3.99 (m, 2H), 4.24 (td, J = 7.1, 4.4, 1H), 5.55 (s, 2H), 6.22 (t, J = 
6.3, 1H), 6.68 (s, 1H), 7.09 (t, J = 8.6, 2H), 7.30 (dd, J = 8.6, 5.2, 
2H), 7.33 (d, J = 14.6, 1H), 7.51 (q, J = 1.1, 1H), 7.97 (s, 1H), 
8.26 (d, J = 14.6, 1H), 15.21 (br s, 1H); 13C NMR (CDCl3, 100.6 
MHz) G–5.4 (CH3), –5.3 (CH3), 13.5 (CH3), 18.4 (C), 25.9 
(CH3), 38.2 (CH2), 53.8 (CH2), 60.3 (CH), 62.8 (CH2), 84.7 (CH), 
85.7 (CH), 99.2 (CH), 109.9 (C), 116.3 (d, J = 22.0, CH), 118.6 
(CH), 125.1 (CH), 129.7 (d, J = 3.0, C), 130.2 (d, J = 8.5, CH), 
130.5 (CH), 133.3 (CH), 147.0 (C), 149.5 (C), 162.1 (C), 163.0 
(d, J = 249.2, C), 178.1 (C), 183.2 (C). 
 Spectral data of 9: 1H NMR (CDCl3, 400 MHz) G 0.14 (s, 6H), 
0.94 (s, 9H), 1.97 (d, J = 1.2, 3H), 2.27 (td, J = 13.6, 6.8, 1H), 2.52 
(ddd, J = 13.6, 5.8, 4.7, 1H), 3.83 (dd, J = 11.5, 2.1, 1H), 4.00 (m, 
2H), 4.25 (td, J = 7.2, 4.3, 1H), 5.95 (s, 2H), 6.22 (t, J = 6.3, 1H), 
6.78 (s, 1H), 7.04 (t, J = 8.6, 2H), 7.37 (d, J = 14.5, 1H), 7.44 (dd, 
J = 8.7, 5.3, 2H), 7.54 (q, J = 1.2, 1H), 8.39 (d, J = 14.6, 1H), 
14.70 (br. s, 1H); 13C NMR (CDCl3, 100.6 MHz)G–5.4 (CH3), –
5.3 (CH3), 13.5 (CH3), 18.5 (C), 25.8 (CH3), 38.2 (CH2), 52.3 
(CH2), 60.4 (CH), 62.8 (CH2), 84.7 (CH), 85.7 (CH), 101.2 (CH), 
110.0 (C), 115.8 (d, J = 21.8, CH), 118.8 (CH), 128.9 (d, J = 3.2, 
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C), 130.8 (d, J = 8.5, CH), 130.5 (CH), 133.3 (CH), 149.2 (C), 
149.6 (C), 161.9 (C), 163.4 (d, J = 248.2, C), 177.9 (C), 180.2 (C). 
15. 10: 1H NMR (CDCl3, 400 MHz) G 1.96 (d, J = 0.6, 3H), 2.49 (m, 
2H), 3.88 (dd, J = 11.7, 2.4, 1H), 4.00 (td, J = 5.2, 2.5, 1H), 4.06 
(dd, J = 11.8, 2.4, 1H), 4.40 (td, J = 11.9, 6.5, 1H), 5.95 (s, 2H), 
6.16 (t, J = 6.2, 1H), 6.77 (s, 1H), 7.04 (t, J = 8.7, 2H), 7.35 (d, J 
= 14.6, 1H), 7.44 (dd, J = 8.8, 5.2, 1H), 7.60 (m, 1H), 8.38 (d, J = 
14.6, 1H), 14.70 (br. s, 1H); 13C NMR (CDCl3, 100.6 MHz) 
G13.4 (CH3), 37.8 (CH2), 52.2 (CH2), 59.5 (CH), 61.8 (CH2), 
84.6 (CH), 87.0 (CH), 101.1 (CH), 110.0 (C), 115.9 (d, J = 21.7, 
CH), 116.4 (CH), 129.7 (d, J = 3.3, C), 130.7 (d, J = 8.4, CH), 
132.7 (CH), 134.9 (CH), 149.1 (C), 149.4 (C), 161.9 (C), 162.9 
(d, J = 248.7, C), 178.5 (C), 179.8 (C). 
 11: 1H NMR (CDCl3, 400 MHz) G 1.96 (d, J = 1.0, 3H), 2.99 (m, 
2H), 3.86 (dd, J = 11.9, 2.6, 1H), 4.00 (td, J = 5.1, 2.4, 1H), 4.05 
(dd, J = 11.9, 2.6, 1H), 4.40 (td, J = 7.1, 5.5, 1H), 5.55 (s, 2H), 6.13 
(t, J = 6.3, 1H), 6.67 (s, 1H), 7.09 (t, J = 8.6, 2H), 7.30 (dd, J = 8.6, 
5.2, 2H), 7.31 (d, J = 14.6, 1H), 7.52 (m, 1H), 7.98 (s, 1H), 8.23 (d, 
J = 14.6, 1H), 15.35 (br. s, 1H); 13C NMR (CDCl3, 100.6 MHz) 
G13.4 (CH3), 37.7 (CH2), 53.8 (CH2), 59.6 (CH), 61.8 (CH2), 84.6 
(CH), 87.2 (CH), 99.2 (CH), 110.2 (C), 116.4 (d, J = 21.7, CH), 
118.2 (CH), 125.2 (CH), 128.6 (CH), 129.6 (d, J = 3.3, C), 130.2 
(d, J = 8.5, CH), 130.6 (CH), 134.7 (CH), 144.4 (C), 147.0 (C), 
149.5 (C), 161.9 (C), 163. 2 (d, J = 249.6, C), 178.2 (C), 183.2 (C). 
16. Under the following conditions: 100 nM of HIV-1 IN (B strain), 
10 mM MgCl2, pH 7.0, 37 ºC, according to: (a) Deprez, E.; 
Barbe, S.; Kolaski, M.; Leh, H.; Zouhiri, F.; Auclair, C.; Brochon, 
J. C.; Le Bret, M.; Mouscadet, J. F. Mol. Pharmacol. 2004, 65, 
85–98; (b) Delelis, O.; Malet, I.; Na, L.; Tchertanov, L.; Calvez, 
V.; Marcelin, A. G., Subra, F., Deprez, E.; Mouscadet, J. F. Nucl. 
Ac. Res. 2009, 37, 1193–1201. Stock solutions were prepared in 
DMSO at concentrations of 10 mg/mL. HeLa-CD4+-E-gal 
reporter cells were infected in triplicate with an amount of 3 ng of 
p24 antigen in the presence of increasing concentrations of the 
drug candidates. The EC50 values were determined 48 h post 
infection as the concentration of drug inhibiting E-galactosidase 
production by 50% in comparison to results for the untreated 
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